State Street SPDR S&P Biotech ETF (XBI)


Market Price (8/31/2026): $160.15

State Street SPDR S&P Biotech ETF (XBI)


Market Price (8/31/2026): $160.15

Key Takeaways

  • XBI has returned +33.2% YTD vs +13.1% for SPY; +81.4% over the past 12 months (SPY +20.3%). details →
  • Priced in gold, XBI has returned -10.4% over the past 3 years, vs +106.1% in dollars — its dollar gains have lagged gold. details →
  • Over the past month, XBI has seen net inflows of +$733M (+6.8% of assets). details →
  • Only 31% of XBI's portfolio (by weight) is currently profitable, vs 98% for SPY. details →
  • XBI's +33.2% YTD is ahead of its typical pace — it averaged -4.6% at this point (August 30) over the past 5 years. details →
Last updated: 8/30/2026.

Price Chart

Asset Allocation with XBI

Risk Tolerance:
ConservativeModerateAggressive
Moderate — 55% equity / 25% bonds / 20% alternatives
10Y Return (ann.)
+9.6%
Volatility
16.4%
Sharpe
0.47
YTD
+20.3%
Modeled with monthly rebalancing to target weights; 10-year figures are annualized from monthly returns. Illustrative only — past performance is not indicative of future results.

Learn More →
Tailored Asset Allocation
[1] Personalized 5 Level Risk Tolerance Assessment
[2] Asset Allocation for My Risk Tolerance
Learn More →
Protect Wealth
[1] Defensive Portfolios
[2] Tax-Efficient Strategies

Valuation & Yield

 Forward [4,5]NowHistorical (CYE & TTM)
 8/31/278/31/2620252024202320222021
Share Price CYE $162.38$121.93$89.72$88.83$82.56$111.36
Dividend/Share TTM $0.43$0.45$0.13$0.02$0.00$0.04

Valuation [1]
       
P/S7.799.078.297.518.075.0020.33
P/E 23.4620.1722.1728.4816.2111.20
P/E (Non-GAAP) [2]48.3566.2448.3046.73109.15107.5693.02
P/FCF 

Yields TTM
       
Earnings Yield2.07%4.26%4.96%4.51%3.51%6.17%8.93%
Dividend Yield0.27%0.27%0.37%0.15%0.02%0.00%0.04%
Total Yield (TY)2.34%4.53%5.32%4.66%3.53%6.17%8.96%

Risk Premium [3]
       
Risk Free Rate (Rf)4.67%4.67%4.18%4.58%3.88%3.88%1.52%
Risk Prem. (TY - Rf)-2.33%-0.14%1.14%0.08%-0.35%2.29%7.44%

Growth Rates [6]
       
Sales Growth16.2%1.8%24.4%14.5%-11.0%8.0% 
Earnings Growth [7]       

[1] P/E uses the aggregate method over profitable constituents; P/FCF aggregates net free cash flow across all constituents (negative-FCF names reduce it); P/S uses all constituents. Ratios reflect current ETF holdings at current weights. P/FCF has no Forward column (no analyst FCF estimate).
[2] P/E (Non-GAAP) uses analyst consensus net income (adjusted basis) for all periods. The standard P/E row above uses GAAP net income.
[3] The premium above the risk free rate (US 10Y) offered by the investment. Negative premiums can indicate stretched valuations.
Show more
[4] Forward P/S and Forward P/E determined as:
  (a) Aggregate using constituent analyst consensus. FY1/FY2 blended by months of overlap to the 12-month window ending 8/31/27.
  (b) Uses current weights and market caps. Shown only when ≥90% of weight has estimates.
[5] Forward dividend yield and risk-free rate are carried at current, not projected.
[6] Growth Rates:
  (a) Weighted by current constituent weights. Shown when ≥90% of weight is covered.
  (b) Now and Historical columns show realized year-over-year change.
  (c) Forward growth rates using next fiscal year (FY2) vs. current fiscal year (FY1) consensus. This differs from the blended target date used for calculating Forward P/S and P/E.
[7] Earnings Growth reflects:
  (a) Non-GAAP earnings growth for forward earnings using next fiscal year (FY2) vs. current fiscal year (FY1) consensus.
  (b) GAAP earnings growth for Now and Historical growth rates.

Highlights
YIELD
XBI's earnings yield is 4.26%, based on its 23.5x trailing P/E. With a 0.27% dividend yield, XBI is yielding 4.53% in total.
RISK
Compared to US Treasuries at 4.67%, XBI's total yield implies a -0.14% risk premium. A negative risk premium means investors earn less than risk-free Treasuries — valuations are historically stretched, though expectations of falling interest rates or fast earnings growth can justify such levels.
FORWARD EXPECTATIONS
Based on analyst estimates, XBI's forward total yield is 2.34%, implying a -2.33% risk premium assuming stable Treasury rates.

Top 20 Holdings for XBI

Total Weights
Top 5: 9.0% | Top 10: 15.7% | Top 20: 27.9%

TickerHoldingETF WeightSales WeightEarnings WeightFwd P/SFwd P/EFwd Sales GrowthFwd Earnings Growth
Total68.98%100.00%100.00%7.446.3+16.2%+14.5%
Top 2017.53%11.40%12.82%14.655.1+18.8%-3.8%
MRNAModerna2.76%1.37%23.9+14.3%
TWSTTwist Bioscience2.01%1.21%16.4+19.3%
APGEApogee Therapeutics1.45%
NTRANatera1.39%0.99%14.2+19.7%
KYMRKymera Therapeutics1.37%0.15%184.3-61.1%
RVMDRevolution Medicines1.36%
PRAXPraxis Precision Medicines1.36%
HALOHalozyme Therapeutics1.35%2.24%4.85%6.210.2+11.5%+22.7%
ORKAOruka Therapeutics1.34%
DNTHDianthus Therapeutics1.30%0.01%2,990.6+8.5%
ERASErasca1.30%
TVTXTravere Therapeutics1.28%1.52%6.415.8+49.5%
CGONCG Oncology1.28%0.01%118.8+1,783.9%
PTGXProtagonist Therapeutics1.26%0.46%1.18%31.196.5-64.0%-105.2%
PCVXVaxcyte1.20%
SRRKScholar Rock1.19%
REGNRegeneron Pharmaceuticals1.19%2.80%6.79%4.512.9+9.0%+12.6%
ROIVRoivant Sciences1.18%0.00%130.7+665.7%
SLSSELLAS Life Sciences1.17%
INSMInsmed1.17%0.64%10.28,754.3+60.7%
[1] Total and Top 20 rows are weighted aggregates across constituents.
[2] Forward P/S and P/E ratios use consensus sales and earnings for the 12 months ending 8/31/27. Individual constituent FY1 and FY2 consensus figures adjusted to align with 8/31/27.
[3] Forward Sales and Non-GAAP Earnings Growth are calculated as next fiscal year (FY2) consensus growth over current fiscal year (FY1) consensus. They are not derived from the forward P/S and P/E multiples shown.

Performance for XBI Top Holdings

TickerHoldingWeightMkt Price
8/30
1D Rtn1M RtnYTD Rtn1Y Rtn3Y Rtn5Y Rtn10Y Rtn
XBIState Street SPDR S&P Biotech ETF100.00%162.380.0%10.5%33.2%81.4%106.1%22.9%172.7%
MRNAModerna2.76%137.990.0%151.7%367.9%472.8%22.0%-63.4% 
TWSTTwist Bioscience2.01%141.380.0%54.4%345.7%424.2%542.9%24.9% 
APGEApogee Therapeutics1.45%134.970.0%0.7%78.8%271.1%488.4%  
NTRANatera1.39%326.260.0%21.8%42.4%93.9%455.5%175.5%3,143.1%
KYMRKymera Therapeutics1.37%118.150.0%14.3%51.8%186.8%519.2%90.1% 
RVMDRevolution Medicines1.36%207.880.0%10.9%161.0%447.5%512.0%614.6% 
PRAXPraxis Precision Medicines1.36%344.750.0%12.0%17.0%657.0%1,463.5%15.7% 
HALOHalozyme Therapeutics1.35%105.350.0%27.6%56.5%44.0%147.5%150.9%956.7%
ORKAOruka Therapeutics1.34%91.140.0%-5.6%200.7%515.8%588.9%357.0%-72.4%
DNTHDianthus Therapeutics1.30%105.840.0%-1.0%156.8%349.0%14,012.0%1,553.7% 
ERASErasca1.30%18.030.0%-0.7%384.7%1,048.4%596.1%-24.6% 
TVTXTravere Therapeutics1.28%65.670.0%17.5%71.9%275.3%359.9%200.8%301.7%
CGONCG Oncology1.28%74.340.0%4.4%79.0%177.2%   
PTGXProtagonist Therapeutics1.26%144.330.0%5.6%65.3%144.4%628.2%197.6%1,093.8%
PCVXVaxcyte1.20%59.840.0%10.6%29.7%94.3%15.2%128.1% 
SRRKScholar Rock1.19%57.800.0%22.2%31.2%77.0%824.8%46.2% 
REGNRegeneron Pharmaceuticals1.19%794.190.0%4.3%3.3%37.5%-3.0%19.1%103.8%
ROIVRoivant Sciences1.18%34.710.0%2.4%60.0%190.9%200.0%248.8% 
SLSSELLAS Life Sciences1.17%13.210.0%32.0%250.4%588.0%798.6%42.2%-99.9%
INSMInsmed1.17%118.540.0%20.2%-31.9%-12.9%441.5%322.8%785.3%

Guidance Updates for XBI Top Holdings

 TickerCompanyEarnings DateGuidance MetricMidpoint Value% ChangeGuidance Change
HALO_8062026HALOHalozyme Therapeutics8/6/20262026 Total Revenue1.87 Bil6.4%RaisedRaised Prior Guidance of 1.76 Bil for 2026
INSM_8062026INSMInsmed8/6/20262026 BRINSUPRI Revenue1.32 Bil32.5%RaisedRaised Prior Guidance of 1.00 Bil for 2026

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
XBI Return-20%-26%8%1%36%38%20%
Peers Return33%-5%32%13%33%44%258%
S&P 500 Return27%-19%24%23%16%13%106%

Monthly Win Rates [3]
XBI Win Rate33%50%50%50%67%88% 
Peers Win Rate63%48%58%57%67%65% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
XBI Max Drawdown-37%-46%-30%-20%-26%-11% 
Peers Max Drawdown-18%-35%-16%-18%-27%-20% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: SMH, SOXX, IBB, ITA, XOP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/28/2026 (YTD)

Sharpe Ratios Compared

One measure of reward vs. risk is a Sharpe ratio. A higher ratio indicates better risk-adjusted returns. Most funds have Sharpe ratios < 1.0.

Ticker1Y3Y5Y
XBI1.970.660.16
Equity Top Results (3Y)   
IALT2.112.112.11
SPMO0.891.380.82
VLUE2.491.260.69
CORO1.331.251.25
CGDV1.351.230.94

Results as of 7312026.

How Low Can It Go

EventXBIS&P 500
2025 US Tariff Shock
  % Loss-24.6%-18.8%
  % Gain to Breakeven32.6%23.1%
  Time to Breakeven147 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-22.9%-9.5%
  % Gain to Breakeven29.7%10.5%
  Time to Breakeven47 days24 days
2023 SVB Regional Banking Crisis
  % Loss-14.5%-6.7%
  % Gain to Breakeven17.0%7.1%
  Time to Breakeven48 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-45.6%-24.5%
  % Gain to Breakeven83.8%32.4%
  Time to Breakeven1290 days427 days
2020 COVID-19 Crash
  % Loss-32.9%-33.7%
  % Gain to Breakeven49.1%50.9%
  Time to Breakeven53 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-31.1%-19.2%
  % Gain to Breakeven45.0%23.8%
  Time to Breakeven351 days105 days

Compare to SMH, SOXX, IBB, ITA, XOP

In The Past

State Street SPDR S&P Biotech ETF's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventXBIS&P 500
2025 US Tariff Shock
  % Loss-24.6%-18.8%
  % Gain to Breakeven32.6%23.1%
  Time to Breakeven147 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-22.9%-9.5%
  % Gain to Breakeven29.7%10.5%
  Time to Breakeven47 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-45.6%-24.5%
  % Gain to Breakeven83.8%32.4%
  Time to Breakeven1290 days427 days
2020 COVID-19 Crash
  % Loss-32.9%-33.7%
  % Gain to Breakeven49.1%50.9%
  Time to Breakeven53 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-31.1%-19.2%
  % Gain to Breakeven45.0%23.8%
  Time to Breakeven351 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-21.4%-3.7%
  % Gain to Breakeven27.2%3.9%
  Time to Breakeven11 days6 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-42.3%-12.2%
  % Gain to Breakeven73.2%13.9%
  Time to Breakeven497 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-26.7%-17.9%
  % Gain to Breakeven36.5%21.8%
  Time to Breakeven172 days123 days
2008-2009 Global Financial Crisis
  % Loss-29.1%-53.4%
  % Gain to Breakeven41.0%114.4%
  Time to Breakeven371 days1085 days

Compare to SMH, SOXX, IBB, ITA, XOP

In The Past

State Street SPDR S&P Biotech ETF's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

XBI Dip Buy History


Get Notified
Alerts when dip buy opportunities arise.
Notify Me →

Current Dip Buy Opportunities Across ETFs

ETFs currently down 5% or more from trailing 6M peaks.

TickerNameDip %Mkt PricePrice DatePeak PricePeak Date# Days
SCHASchwab U.S. Small-Cap ETF-5.2%34.24830202636.13630202661
EEMiShares MSCI Emerging Markets ETF-5.7%67.14830202671.21622202669
ASHRXtrackers Harvest CSI 300 China A-Shares ETF-8.1%34.29830202637.30622202669
EWYiShares MSCI South Korea ETF-17.8%180.208302026219.20621202670
EWZiShares MSCI Brazil ETF-14.8%35.55830202641.734142026138
FXIiShares China Large-Cap ETF-7.2%35.51830202638.265132026109
ILFiShares Latin America 40 ETF-9.1%34.65830202638.104142026138
KWEBKraneShares CSI China Internet ETF-15.3%26.32830202631.063012026182
MTUMiShares MSCI USA Momentum Factor ETF-13.2%299.718302026345.22622202669
SPMOInvesco S&P 500 Momentum ETF-9.2%146.788302026161.66622202669
URAGlobal X Uranium ETF-21.8%45.57830202658.265062026116
BOTZGlobal X Funds Global X Robotics & Artificial Intelligence ETF-14.1%35.75830202641.635132026109
ROBOROBO Global Robotics & Automation Index ETF-10.7%80.64830202690.34602202689
LITGlobal X Lithium & Battery Tech ETF-17.0%76.07830202691.625112026111
ICLNiShares Global Clean Energy ETF-26.4%17.48830202623.75602202689
ARKQARK Autonomous Technology & Robotics ETF-14.9%122.328302026143.82528202694
ARKXARK Space & Defense Innovation ETF-14.3%32.35830202637.74528202694
NASATema Space Innovators ETF-44.1%23.41830202641.89527202695
AGIXKraneShares Artificial Intelligence ETF-8.8%45.03830202649.40601202690
XLKState Street Technology Select Sector SPDR ETF-6.3%185.698302026198.21602202689
XLIState Street Industrial Select Sector SPDR ETF-5.0%177.148302026186.51816202614
XLCState Street Communication Services Select Sector SPDR ETF-5.1%112.998302026119.104192026133
XLUState Street Utilities Select Sector SPDR ETF-9.8%42.73830202647.403012026182
SMHVanEck Semiconductor ETF-17.3%553.118302026668.91622202669
SOXXiShares Semiconductor ETF-22.3%508.628302026655.01622202669
ITAiShares U.S. Aerospace & Defense ETF-8.1%232.828302026253.22816202614
MISLFirst Trust Indxx Aerospace & Defense ETF-11.9%44.64830202650.663022026181
RINGiShares MSCI Global Gold Miners ETF-12.0%87.46830202699.423012026182
SOXQInvesco PHLX Semiconductor ETF-21.6%90.288302026115.11622202669
TLTiShares 20+ Year Treasury Bond ETF-7.0%82.88830202689.153012026182
VGLTVanguard Long-Term Treasury ETF-5.9%53.18830202656.533012026182
SPTLState Street SPDR Portfolio Long Term Treasury ETF-6.3%25.29830202626.993012026182
TLHiShares 10-20 Year Treasury Bond ETF-5.6%97.298302026103.083012026182
EDVVanguard World Funds Extended Duration ETF-10.0%60.66830202667.423012026182
COMTiShares GSCI Commodity Dynamic Roll Strategy ETF-5.6%34.48830202636.535192026103
GSGiShares GSCI Commodity-5.8%30.01830202631.853182026165
GLDSPDR Gold Trust-16.6%408.898302026490.003022026181
IAUiShares Gold Trust-16.5%83.828302026100.383022026181
GLDMSPDR Gold MiniShares Trust-16.4%88.208302026105.543022026181
SGOLETFS Physical Swiss Gold Shares-12.1%44.66830202650.813022026181
BARDirexion Daily Gold Bull 3X Shares-15.6%44.34830202652.533022026181
SLViShares Silver Trust-29.4%60.02830202684.993012026182
SIVRETFS Physical Silver Shares Trust ETF-6.6%83.39830202689.263012026182
PPLTETFS Physical Platinum Shares-23.2%16.49830202621.473012026182
CPERUnited States Copper Index Fund ETV-9.6%33.33830202636.883012026182
PALLETFS Physical Palladium Shares-20.6%25.79830202632.483012026182
USOUnited States Oil Fund LP-15.2%129.708302026152.965192026103
UNGUnited States Natural Gas Fund LP-20.8%10.33830202613.043122026171
BNOUnited States Brent Oil Fund LP ETV-7.1%55.85830202660.135042026118
USRTiShares Core U.S. REIT ETF-5.3%66.13830202669.82726202635
IBITiShares Bitcoin Trust ETF-5.5%43.90830202646.475112026111
FBTCFidelity Wise Origin Bitcoin Fund-5.5%67.44830202671.355112026111

ETF Fund Flows

Largest fund inflows and outflows across ETFs, with the asset-allocation rotation they imply.

Net fund flows · as of 2026-08-28

Asset allocation rotation · Past month

  • Equity ETFs drew the largest net inflows (+$47.7B), followed by Bond (+$17.6B), while Real Estate (−$101M) saw the largest outflows.
  • Within the mix, money rotated into US Nasdaq Growth (+$17.6B) and out of Intermediate Treasury (−$8.0B).
  • Relative to fund size, CNEQ drew the largest inflow (+104.0% of AUM) and PKW the largest outflow (−30.8%).
Largest inflows
#TickerNameTypeNet flow% of AUM
1VOOVanguard S&P 500 ETFEquity US Large Cap Core+$21.73B+2.1%
2QQQInvesco QQQ Trust, Series 1Equity US Nasdaq Growth+$14.48B+3.0%
3SGOViShares 0-3 Month Treasury Bond ETFCash+$6.04B+5.9%
4TLTiShares 20+ Year Treasury Bond ETFBond Long Treasury+$5.35B+11.6%
5SPYMState Street SPDR Portfolio S&P 500 ETFEquity US Large Cap Core+$5.29B+3.1%
6GLDSPDR Gold SharesCommodity Gold+$4.82B+3.3%
7VTIVanguard Morningstar Total Stock Market ETFEquity US Total Market+$4.44B+0.6%
8SCHDSchwab U.S. Dividend Equity ETFEquity Dividend Income+$3.66B+3.4%
9AVLVAvantis U.S. Large Cap Value ETFOther+$3.41B+18.2%
10VGSHVanguard Short-Term Treasury ETFBond Short Treasury+$3.25B+10.7%
Largest outflows
#TickerNameTypeNet flow% of AUM
1IVViShares Core S&P 500 ETFEquity US Large Cap Core-$8.96B-1.0%
2IEFiShares 7-10 Year Treasury Bond ETFBond Intermediate Treasury-$5.28B-12.3%
3SPYState Street SPDR S&P 500 ETFEquity US Large Cap Core-$4.64B-0.6%
4XLFState Street Financial Select Sector SPDR ETFEquity Broad Sector-$4.08B-7.0%
5SOXXiShares Semiconductor ETFEquity Industry Subsector-$3.57B-8.3%
6SMHVanEck Semiconductor ETFEquity Industry Subsector-$2.48B-3.5%
7SDYState Street SPDR S&P Dividend ETFEquity Dividend Income-$1.86B-8.4%
8GOVTiShares U.S. Treasury Bond ETFBond Intermediate Treasury-$1.73B-4.0%
9VGITVanguard Intermediate-Term Treasury ETFBond Intermediate Treasury-$1.33B-3.1%
10XLKState Street Technology Select Sector SPDR ETFEquity Broad Sector-$1.31B-1.1%

Largest ETF fund flows across ~2627 funds (min AUM $100M). Net creations/redemptions; leveraged & inverse ETFs excluded. A ⚠ marks a day excluded as a suspected data error.

Set Alerts and Notifications

Stay Informed

Trade & Investment Ideas

Wealth

Alert Me Periodically

Inform Me Once

About XBI

0Holdings Count: 155
Expense Ratio: 0.35%
Inception Date: 2006-01-31
State Street SPDR S&P Biotech ETF
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
Asset Class: Equity | ETF Website

Recent Active Movers

Peer Comparisons

Peers to compare with:

Profile

XBISMHSOXXIBBITAXOPMedian
NameState Stre.VanEck Sem.iShares Se.iShares Bi.iShares U..State Stre. 
Asset ClassEquityEquityEquityEquityEquityEquity-
AUM ($ Bil)12.067.641.710.513.93.913.0
Expense Ratio0.35%0.35%0.33%0.44%0.37%0.35%0.35%
10-D Avg Volume (Mil)8.7510.739.581.550.783.446.10
Latest Day Volume (Mil)1.162.033.340.29-0.251.16
Holdings Count1552630247485150
Inception Date1/31/200612/20/20117/9/20012/4/20014/30/20066/19/2006-

Fundamentals

XBISMHSOXXIBBITAXOPMedian
NameState Stre.VanEck Sem.iShares Se.iShares Bi.iShares U..State Stre. 
Net Asset Value168.23553.12508.44208.98232.77185.42-
Premium/Discount-3.5%-0.0%0.0%-0.0%0.0%0.3%0.0%
Distribution Yield0.4%0.2%0.3%0.2%0.0%1.7%0.2%
Sales Yield8.3%7.7%8.1%12.0%30.5%117.5%10.1%
Earnings Yield1.2%2.6%2.3%1.8%2.7%7.7%2.4%

Valuation

XBISMHSOXXIBBITAXOPMedian
NameState Stre.VanEck Sem.iShares Se.iShares Bi.iShares U..State Stre. 
P/S (TTM)12.1x12.9x12.4x8.3x3.3x0.9x10.2x
P/E (TTM)80.4x39.1x44.3x54.8x37.4x12.9x41.7x
P/FCF (TTM)-47.3x51.7x-39.4x15.9x43.3x
Forward P/E65.4x---31.1x10.6x31.1x
Forward P/S8.2x---3.0x0.8x3.0x

Risk

XBISMHSOXXIBBITAXOPMedian
NameState Stre.VanEck Sem.iShares Se.iShares Bi.iShares U..State Stre. 
Volatility (1Y)28.0%39.3%45.3%21.8%23.0%29.0%28.5%
Volatility (3Y)27.9%36.8%39.4%20.9%20.1%28.2%28.1%
Volatility (5Y)32.4%36.7%38.5%22.2%20.3%33.4%32.9%
Beta (1Y)1.052.392.600.781.03-0.321.04
Beta (3Y)1.031.972.050.820.850.660.94
Beta (5Y)1.161.761.820.860.810.851.01
Sharpe Ratio (1Y)2.251.781.792.000.811.401.79
Sharpe Ratio (3Y)1.011.361.160.901.300.511.08
Sharpe Ratio (5Y)0.341.000.850.320.930.790.82
Max Drawdown (1Y)-10.5%-24.6%-29.0%-9.6%-15.8%-18.7%-17.3%
Max Drawdown (3Y)-33.0%-35.7%-41.4%-24.9%-15.8%-35.0%-34.0%
Max Drawdown (5Y)-54.0%-45.3%-45.8%-39.7%-18.7%-35.0%-42.5%

Returns

XBISMHSOXXIBBITAXOPMedian
NameState Stre.VanEck Sem.iShares Se.iShares Bi.iShares U..State Stre. 
1M Return7.2%2.6%0.8%10.0%-2.2%6.3%4.5%
3M Return18.8%-7.7%-10.6%21.4%-1.1%13.4%6.1%
6M Return27.5%36.1%44.5%19.2%-4.4%21.4%24.5%
YTD Return33.2%53.6%69.0%23.9%8.5%47.9%40.5%
1Y Return80.5%86.4%103.2%51.1%17.4%44.1%65.8%
2Y Return60.6%124.4%120.5%42.0%62.6%39.4%61.6%
3Y Return107.0%267.0%211.1%64.6%105.8%36.9%106.4%

Short Interest

Short Interest: As Of Date8142026
Short Interest: Shares Quantity77.1 Mil
Short Interest: % Change Since 7312026-2.2%
Average Daily Volume7.4 Mil
Days-to-Cover Short Interest10.4 days